Research progress of traditional Chinese medicine in treatment of benign prostatic hyperplasia.
10.19540/j.cnki.cjcmm.20240729.501
- Author:
Sheng-Long LI
1
;
Gang-Gang LU
1
;
Guang-Wei JIN
1
;
Peng-Dong YIN
1
;
Mei-Sheng GONG
2
;
Hui LI
1
;
Xu MA
1
;
Xi-Xiang LI
3
;
Yuan-Bo ZHAO
1
;
Da-Cheng TIAN
1
;
Yong-Lin LIANG
4
;
Yong-Qiang ZHAO
5
Author Information
1. School of Traditional Chinese and Western Medicine, Gansu University of Chinese Medicine Lanzhou 730000, China.
2. Graduate School, Heilongjiang Academy of Chinese Medicine Harbin 150006, China.
3. Pharmacy Department, Gansu Provincial Hospital of Traditional Chinese Medicine Lanzhou 730050, China.
4. School of Basic Medicine, Gansu University of Chinese Medicine Lanzhou 730000, China.
5. Urology Department, Gansu Hospital of Traditional Chinese Medicine Lanzhou 730050, China.
- Publication Type:English Abstract
- Keywords:
basic research;
benign prostatic hyperplasia;
clinical research;
review;
traditional Chinese medicine
- MeSH:
Prostatic Hyperplasia/metabolism*;
Male;
Humans;
Drugs, Chinese Herbal/therapeutic use*;
Animals;
Signal Transduction/drug effects*;
Medicine, Chinese Traditional;
NF-E2-Related Factor 2/genetics*
- From:
China Journal of Chinese Materia Medica
2024;49(21):5817-5828
- CountryChina
- Language:Chinese
-
Abstract:
Benign prostatic hyperplasia(BPH) is a common disease in middle-aged and elderly men, with lower urinary tract symptoms as the main manifestation, severely affecting the quality of life of patients. The pathogenesis of BPH is not yet fully understood, and there are still some challenges and limitations in western medicine treatment for BPH. Therefore, finding new and more effective treatment strategies is urgent. In recent years, many basic and clinical studies have confirmed the important role of traditional Chinese medicine in the treatment of BPH. This article reviews the progress of basic and clinical research in the treatment of BPH with traditional Chinese medicine, and believes that basic research mainly focuses on the active ingredients of Chinese medicine [regulating pathways such as NF-E2-related factor 2(Nrf2)/antioxidant response element(ARE), nuclear factor κB(NF-κB), epidermal growth factor receptor(EGFR)/signal transducer and activator of transcription 3(STAT3), phosphoinositide 3-kinase(PI3K)/protein kinase B(Akt)/mammalian target of rapamycin(mTOR), p38 mitogen-activated protein kinase(p38 MAPK)/forkhead box O subtype(FOXO3a), etc.], single Chinese herbs(regulating inflammatory factors, oxidative stress-related proteins, cell cycle-related proteins, and apoptotic factors, etc.), and Chinese herbal compounds and patent medicines [regulating extracellular signal-regulated kinase(ERK1/2), transforming growth factor-β(TGF-β)/Smad, mitogen-activated protein kinase(MAPK), PI3K/Akt, Nrf2, trefoil factor 2(TFF2)/Wnt, interleukin-6(IL-6)/Janus kinase 2(JAK2)/STAT3, hypoxia-inducible factor 1α(HIF-1α)/vascular endothelial growth factor receptor(VEGFR), etc.], and then play a therapeutic role by inhibiting BPH cell proliferation, oxidative stress, inflammatory response, promoting apoptosis, and inhibiting epithelial-mesenchymal transition. Clinical studies mainly focus on internal treatment, external treatment, combined internal and external treatment, and integrated Chinese and western medicine treatment as the main methods, aiming to improve traditional Chinese medicine syndrome scores, prostate symptom scores, residual urine volume, effective bladder volume, sexual quality of life, increase average urine flow rate, maximum urine flow rate, and promote balance of sex hormone secretion. Through this research, it is hoped to provide some reference ideas for clinical research and drug development for BPH.
